Welcome to our dedicated page for Coeptis Therapeutics news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics stock.
News and press releases about Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) highlight its evolution as a biopharmaceutical and technology company, its cell therapy platforms, and its corporate transactions. Company announcements describe Coeptis as operating biopharmaceutical divisions focused on cell therapy platforms for cancer, autoimmune, and infectious diseases, alongside a Technology Division built around AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group.
Recent news has emphasized developments in Coeptis’ pipeline and partnerships. The company has reported securing exclusive worldwide development and commercialization rights to the GEAR Cell Therapy Platform and forming GEAR Therapeutics, Inc. to advance GEAR-modified NK cells for a broad range of cancers. SNAP Biosciences, a majority-owned subsidiary, has announced a licensing agreement with Monarch Therapeutics to enhance the SNAP-CAR NK cell therapy platform using small-molecule adaptor technology.
Coverage also includes updates on Coeptis’ hybrid business model and technology initiatives. Articles describe how the NexGenAI platform contributes revenue while the company advances its cell therapy research, and how a co-working technology hub in India supports AI, blockchain, and digital transformation projects for the NexGenAI Affiliates Group.
Another key theme in recent news is corporate strategy and capital structure. Coeptis has announced the extinguishment of a convertible note with YA II PN, Ltd, and multiple releases detail a proposed merger with Z Squared Inc., a Dogecoin-focused digital asset mining company. These items cover the filing and effectiveness of a Form S-4 registration statement, the planned spin-out of biopharmaceutical operations, and the intention for the combined company to focus on digital asset mining. Investors and observers can use this news stream to follow Coeptis’ biopharmaceutical progress, technology partnerships, financing actions, and the status of its planned merger with Z Squared.
Coeptis Therapeutics (OTC PINK: COEP) announced on Aug. 19, 2021, its acquisition of two technology assets targeting CD38 cancers from VyGen-Bio, Inc. The assets are CD38-GEAR-NK, a cell therapy product, and CD38-Diagnostic, an in vitro diagnostic tool. This acquisition follows previous option agreements made on May 18, 2021, and aims to enhance treatment paradigms for multiple myeloma and other cancers. Coeptis plans to initiate development programs, highlighting the partnership's potential as a significant value driver for the company.